Alpha Tau Medical to Present Pancreatic Cancer Data at ASCO GI
Ticker: DRTSW · Form: 6-K · Filed: Dec 4, 2025 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: medical-conference, oncology, research-update
TL;DR
Alpha Tau Medical presenting pancreatic cancer abstracts at ASCO GI next year.
AI Summary
Alpha Tau Medical Ltd. announced on December 4, 2025, that two abstracts detailing their Alpha DaRT technology for pancreatic cancer will be presented at the 2026 ASCO GI Symposium. This presentation highlights the company's ongoing research and development in oncology.
Why It Matters
The presentation of research at a major oncology symposium like ASCO GI can validate the company's technology and potentially attract significant interest from clinicians and investors.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a scientific presentation, not a financial event or material change in operations.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- Alpha DaRT (technology) — Company's oncology platform
- 2026 ASCO GI Symposium (event) — Medical conference where abstracts will be presented
- December 4, 2025 (date) — Date of press release
FAQ
What is the specific focus of the two abstracts being presented?
The filing states the abstracts concern Alpha DaRT for pancreatic cancer, but does not provide specific details on the focus of each abstract.
When will the 2026 ASCO GI Symposium take place?
The filing does not specify the exact dates for the 2026 ASCO GI Symposium.
Has Alpha Tau Medical Ltd. previously presented at ASCO GI?
The filing does not provide information on previous presentations by Alpha Tau Medical Ltd. at ASCO GI.
What is Alpha DaRT technology?
The filing identifies Alpha DaRT as the company's technology for pancreatic cancer but does not explain its mechanism of action.
Is this press release considered 'filed' with the SEC?
No, the filing explicitly states that the information in this Report on Form 6-K, including Exhibit 99.1, is being furnished and shall not be deemed 'filed'.
Filing Stats: 305 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2025-12-04 09:02:01
Filing Documents
- ea0268426-6k_alpha.htm (6-K) — 13KB
- ea026842601ex99-1_alpha.htm (EX-99.1) — 9KB
- 0001213900-25-118091.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: December 4, 2025 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 3